Evgen Pharma granted a core patent in Europe and is timely from a commercial perspective

Steve Franklin, CEO of Evgen Pharma, said: “We are delighted by the grant of this core patent in Europe, which further expands our intellectual property position and complements similar grants in the USA, Canada and Australia. This patent grant is timely from a commercial perspective as we are moving close to the announcement of our first Phase II clinical data from SFX-01, which we continue to expect in the first half of this year as part of our ongoing STEM trial in breast cancer.”

Evgen Pharma (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, this morning announced the grant of a key European patent ascribing intellectual property rights to the Company for a method of stabilising sulforaphane, the naturally occurring compound on which SFX-01, the Company’s lead product, is based.

The grant of this core patent, which expires on 23 January 2028, marks another important step in expanding the Company’s worldwide intellectual property estate surrounding sulforaphane and the Company’s synthetic, stabilised version, SFX-01.

This patent represents the Company’s second process patent grant in Europe and follows the announcement of a manufacturing and scale-up grant in October 2017. Composition-of-matter and manufacturing patents have already been granted in the USA. Patents are also granted, or in the process towards being granted, in other key commercial territories.

The European patent announced today, numbered EP2796140 and entitled Stablilized Sulforaphane, can be viewed at this link: https://register.epo.org/application?number=EP14166888&lng=en&tab=main.

Exclusive worldwide rights to the patent are held by Evgen Pharma under the terms of a licence agreement with PharmAgra Labs Inc., the US laboratory that invented SFX-01.

In line with Company policy, an update on less material patent developments, including grants related to the Company’s sulforaphane analogues, will be included as part of the Company’s full year results.

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Evgen Pharma Plc

    More articles like this

    Evgen Pharma Plc

    Your Diet and Breast Cancer

    One in eight women will be diagnosed with breast cancer in their lifetime—of that number, studies show 85 percent of women don’t have a family history. “We know that physical activity makes a difference and we

    Evgen Pharma Plc

    Processed meat ‘linked to breast cancer’

    Regularly eating foods like bacon and sausages may raise the risk of breast cancer, according to researchers. A review of studies found women who ate high levels of processed meat had a 9 percent increased risk

    Evgen Pharma Plc

    Bad food habits could lead to cancer

    Enrich your diet with green tea, curcumin, pomegranate, and broccoli — rich in polyphenol — to keep cancers at bay, a nutritionist said, cautioning that unhealthy eating habits leads to cancer. “The key could be in

    Evgen Pharma Plc

    What are the early signs of MS?

    Multiple sclerosis is a progressive disease of the central nervous system. It occurs when the body’s immune system mistakenly attacks the healthy nerves of the brain and spinal cord. According to the National Multiple Sclerosis Society,

    Evgen Pharma Plc

    Evgen Pharma plc holding an Investor Symposium

    Evgen Pharma plc (LON: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will be holding an Investor Symposium for investors and analysts today at the offices of Buchanan,

    Evgen Pharma Plc

    The Greenest of Greens

    We have all heard these words “Eat your greens” especially when it comes to green leafy vegetables that are rated as some of the best foods. Similarly green vegetables have also been called ‘superfoods’ as the

    Evgen Pharma Plc

    Living with MS and Remaining Positive

    Living with multiple sclerosis (MS) could be compared to having an annoying house guest that never leaves. At first you can tolerate them, but soon your nerves and resilience wear thin. You try to accept and

    Evgen Pharma Plc

    Evgen Pharma plc AGM Statement

    Evgen Pharma plc (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will hold its Annual General Meeting later today in Manchester. At the AGM, the Company’s Chairman, Barry